PIK3CA and breast carcinoma: Fig 6 demonstrates the timing of the assay in the treatment pathway of these 144 patients. All patients presented in this study had a single sample analysed once using the panel; most often, the assay was performed prior to any treatment, with only a few patients having the test done after three or more lines of therapy, usually to facilitate clinical trial entry (e.g., a trial of a PI3K inhibitor in breast cancer [19]).